Evidence map›Paper›PMID 23091246›Full record

ArticleJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2012

Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.

Kenneth Hoyt, Anna Sorace, Reshu Saini

Open access · greenAbstract readControlled Clinical Trial
In one paragraph

Article in Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. 3-D Super-Resolution Ultrasound Imaging for Monitoring Early Changes in Breast Cancer after Treatment with a Vascular-Disrupting Agent.IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium · 2021
    Article
  4. Article
  5. Three-dimensional evaluation of microvascular networks using contrast-enhanced ultrasound and microbubble tracking.IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium · 2020
    Article
  6. Faster motion correction of clinical contrast-enhanced ultrasound imaging using deep learning.IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium · 2020
    Article
  7. Multiscale quantification of tumor microarchitecture for predicting therapy response using dynamic contrast-enhanced ultrasound imaging.IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium · 2019
    Article
  8. Contrast-enhanced ultrasound imaging of acute changes in pancreatic cancer following targeted hyaluronan treatment.IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Antibody-based imaging strategies for cancer.Cancer metastasis reviews · 2014
    Review
  15. Volumetric contrast-enhanced ultrasound imaging of renal perfusion.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2014
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kenneth HoytDepartment of Radiology, University of Alabama at Birmingham, G082 Volker Hall, 1670 University Blvd, Birmingham, AL 35294, USA. hoyt@uab.edu
Anna Sorace
Reshu Saini
University of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHAEL JAMES BERTRAM · 1985 to 2026
$165.9M
UAB Rexinoids for Breast Cancer PreventionP50CA089019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLAND, KIRBY I. · 2000 to 2011
$26.0M
NCI NIH HHS 5P50CA089019NCI NIH HHS CA13148NCI NIH HHS P30 CA013148NCI NIH HHS P50 CA089019
6 · The paper itself

Abstract

objectivesThe objective of this study was to determine whether volumetric contrast-enhanced ultrasound (US) imaging could detect early tumor response to anti-death receptor 5 antibody (TRA-8) therapy alone or in combination with chemotherapy in a preclinical triple-negative breast cancer animal model.

methodsAnimal experiments had Institutional Animal Care and Use Committee approval. Thirty breast tumor-bearing mice were administered Abraxane (paclitaxel; Celgene Corporation, Summit, NJ), TRA-8, TRA-8 + Abraxane, or saline as a controlon days 0, 3, 7, 10, 14, and 17. Volumetric contrast-enhanced US imaging was performedon days 0, 1, 3, and 7 before dosing. Changes in parametric maps of tumor perfusion were compared with the tumor volume and immunohistologic findings.

resultsTherapeutic efficacy was detected within 7 days after drug administration using parametric volumetric contrast-enhanced US imaging. Decreased tumor perfusion was observed in both the TRA-8-alone- and TRA-8 + Abraxane-dosed animals compared to control tumors (P = .17; P = .001, respectively). The reduction in perfusion observed in the TRA-8 + Abraxane group was matched with a corresponding regression in tumor size over the same period. Survival curves illustrate that the combination of TRA-8 + Abraxane improves drug efficacy compared to the same drugs administered alone. Immunohistologic analysis revealed increased levels of apoptotic activity in the TRA-8-dosed tumors, confirming enhanced antitumor effects.

conclusionsPreliminary results are encouraging, and volumetric contrast-enhanced US-based tumor perfusion imaging may prove clinically feasible for detecting and monitoring the early antitumor effects in response to combination TRA-8 + Abraxane therapy.

Indexed as

FluorocarbonsAnimalsAntibodies, MonoclonalAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorContrast MediaFemaleHumansImaging, Three-DimensionalMiceMice, NudePrognosisReceptors, TNF-Related Apoptosis-Inducing LigandReproducibility of ResultsAntibodies, MonoclonalAntineoplastic AgentsContrast MediaFluorocarbonsperflutrenReceptors, TNF-Related Apoptosis-Inducing LigandTRA-8 monoclonal antibody

Identifiers

PMID23091246
PMCPMC3560397
OpenAlexW2114428020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.